FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
70 letters match. Newest first.
-
DrugsUmicore Argentina S.A.
CGMP/Active Pharmaceutical Ingredient (API)/Adulterated
-
DrugsNanjing Hanxin Pharmaceutical Technology Co. Ltd.
FDA warns Nanjing Hanxin of drug-ingredient quality failures and poor supplier oversight; its drugs face U.S. import detention.
High risk -
DrugsChongqing Qiancan Technology Co., Ltd.
Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.
High risk -
DrugsTianjin Healthcare Medical Technology Co., Ltd.
Chinese API maker refused FDA records requests, and all its drugs now face a US import alert.
High risk -
DrugsCuria New York, Inc.
FDA warned Curia New York's Rensselaer, New York API plant that undocumented lab injections, shredded records and shared passwords violate CGMP.
High risk -
DrugsKellin Chemicals Co., Ltd. - Zhangjiagang
Kellin Chemicals' API site refused FDA inspection, so FDA calls its drugs adulterated.
High risk -
DrugsShoolin Pharma Chem LLP
Shoolin Pharma Chem, an Indian API maker, warned over filthy conditions, missing test data, and cleaning failures; all U.S. APIs recalled.
High risk -
DrugsTianjin Kilo Pharmaceutical Sci-tech Co., Ltd.
Tianjin Kilo Pharmaceutical Sci-tech, a drug ingredient maker, cited for quality failures and missing listings for demecarium bromide and chlorambucil.
High risk -
DrugsAlmon Healthcare Private Limited
Almon Healthcare, an Indian active pharmaceutical ingredient (API) maker, knowingly used mislabeled, untested raw material and shipped affected drugs to the U.S.
High risk -
DrugsShimoga Chemicals
FDA warns Shimoga Chemicals of manufacturing quality and data integrity failures in clomiphene citrate active ingredient.
High risk -
DrugsFareva Amboise
FDA warned Fareva Amboise in France about sterile drug manufacturing failures, including aseptic practice and data integrity problems.
High risk -
DrugsInternational Medication Systems Limited
FDA found insect larvae and heavy microbial growth in International Medication Systems' sterile filling area; its epinephrine injection lot was later recalled.
High risk -
DrugsPharmathen International S.A.
FDA warns Pharmathen over inadequate aseptic controls at its Greek plant making sterile drugs for the U.S.
High risk -
DrugsHubei Gedian Humanwell Pharmaceutical Co., Ltd.
FDA: Hubei Gedian Humanwell API plant has scratched, stained equipment and weak quality unit oversight.
High risk -
DrugsAlchymars ICM SM Private Limited
FDA found Alchymars API manufacturing had poor equipment and facility maintenance, making its APIs adulterated and prompting an import alert.
High risk -
DrugsHarbin Jixianglong Biotech Co., Ltd.
FDA warned Harbin Jixianglong Biotech over CGMP (manufacturing quality rules) failures and misbranded relabeled semaglutide API with false manufacturer labels and missing drug listings.
High risk -
DrugsHangzhou Yiqi Biotechnology Co., Ltd
FDA cited Hangzhou Yiqi Biotechnology, an API maker in China, for four manufacturing practice failures found in a records review.
High risk -
DrugsAva Inc.
FDA warned Ava Inc. about adulterated drugs after an inspection found data-integrity failures and hidden trial injections in its Willowbrook, Illinois lab.
High risk -
AnimalHenan Lvyuan Pharmaceutical Co. Ltd.
FDA warns Henan Lvyuan Pharmaceutical over CGMP failures at its API plant, including water leaks and incomplete batch records.
High risk -
DrugsFlowchem Pharma Private Limited
FDA warned India's Flowchem Pharma over dirty API equipment, exposed materials and untested impurities, and blocked its drug imports.
High risk -
DrugsA. Nelson & Co. Ltd.
London homeopathic drug maker A. Nelson & Co. shipped children's products without microbial testing and discarded quality records.
High risk -
DrugsChemspec Chemicals Private Limited
FDA warns Indian API maker Chemspec Chemicals over missing batch records and data integrity failures.
High risk -
DrugsDarmerica, LLC
FDA warns Darmerica over manufacturing-quality violations and mislabeled drug ingredients, including retatrutide.
High risk -
DrugsCdymax India Pharma Private Limited
FDA warned Cdymax (India) Pharma that its Bangalore API plant had inadequate out-of-specification investigations and unvalidated test methods, making its APIs adulterated.
High risk -
DrugsSeema International
FDA warns Seema International over unclean API equipment, missing stability data, and quality-unit failures after inspection; APIs adulterated.
High risk -
DrugsScientific Protein Laboratories, LLC
FDA warns Scientific Protein Laboratories over manufacturing failures in animal-derived APIs, including equipment particles and inadequate investigations.
High risk -
DrugsChengdu Brilliant Biopharmaceutical Co., Ltd.
FDA warns Chengdu Brilliant over CGMP failures in semaglutide API, including no process validation and missing raw-material identity tests.
High risk -
DrugsHikal Limited
FDA warned India's Hikal Limited that unresolved metal-particle complaints in its APIs and weak supplier oversight make its active ingredients adulterated.
High risk -
DrugsMacsen Drugs
FDA cites Macsen Drugs for releasing fire-exposed APIs and inadequate stability data at India plant.
High risk -
DrugsMentha & Allied Products Private Ltd.
FDA warns Mentha & Allied Products of CGMP failures that leave its APIs adulterated.
High risk -
DrugsAspen Biopharma Labs Private Limited
FDA warns Aspen Biopharma Labs over current good manufacturing practice failures in active ingredient manufacturing after U.S. recall.
High risk -
DrugsVegewax Candleworx Ltd.
FDA warns Vegewax Candleworx over CGMP violations in OTC drug manufacturing, including inadequate component testing and OOS investigations.
High risk -
DrugsShree Jaya Laboratories PVT. LTD.
FDA warned Shree Jaya Laboratories after an inspection found CGMP deviations in API and intermediate manufacturing, including dirty equipment and torn batch records.
High risk -
DrugsTyche Industries Ltd
FDA warned Tyche Industries over falsified records, dirty equipment, and untested raw materials at its API plant.
High risk -
DrugsJagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals cited for API CGMP and listing failures after Indian inspection, leading to US import alert.
High risk -
DrugsChengdu Innovation Pharmaceutical Co., Ltd.
FDA warned Chengdu Innovation Pharmaceutical over CGMP (manufacturing quality rules) failures in API (drug ingredient) manufacturing, including no identity testing of incoming materials.
High risk -
DrugsWuhu Nuowei Chemistry Co., Ltd.
FDA cited Wuhu Nuowei Chemistry for API CGMP deviations in impurity testing, stability data, and cleaning, and placed products on import alert.
High risk -
DrugsCenter for Instrumental Analysis of China Pharmaceutical University
Center for Instrumental Analysis of China Pharmaceutical University cited for incomplete API testing records and no quality unit.
High risk -
DrugsGlobal Calcium Pvt. Limited
FDA cites Global Calcium API plant for falsified records, deleted files, facility leaks and incomplete impurity profiles; products on Import Alert 66-40.
High risk -
DrugsSanofi
FDA warned Sanofi subsidiary Genzyme over manufacturing quality failures at its Framingham, MA API plant.
High risk -
DrugsBhargava Phytolab Private Limited
FDA warns Bhargava Phytolab over drug and API current good manufacturing practice (CGMP) violations, including inadequate testing and sterility controls.
High risk -
DrugsMicro Orgo Chem
Micro Orgo Chem in India failed CGMP for API drugs, including cleaning, process validation, stability and records.
High risk -
DrugsSani-Care Salon Products, Inc.
FDA warns Sani-Care Salon Products over CGMP failures in hand sanitizer manufacturing, including inadequate quality oversight and testing.
High risk -
DrugsAntaria Pty. Ltd.
FDA warned Antaria Pty. Ltd. about manufacturing quality failures in its active drug ingredient, including poor out-of-specification investigations and testing.
High risk -
DrugsSichuan Deebio Pharmaceutical Co. Ltd.
FDA warns Sichuan Deebio Pharmaceutical over API manufacturing and data-integrity failures.
High risk -
DrugsMei Lan Thailand Co., Ltd.
CGMP/Active Pharmaceutical Ingredient (API)/Adulterated/Refused Inspection
-
DrugsALI Pharmaceutical Manufacturing, LLC
CGMP/Active Pharmaceutical Ingredient (API)/Adulterated
-
DrugsSun Pharmaceutical Industries Ltd.
FDA warns Sun Pharmaceutical over CGMP violations in sterile injectable manufacturing at its Halol, India facility.
High risk -
DrugsCentaur Pharmaceuticals Private Ltd.
FDA warns Centaur Pharmaceuticals over manufacturing practice failures in active ingredients, including records and cleaning.
High risk -
DrugsChengdu KeCheng Fine Chemicals Co., Ltd.
FDA placed Chengdu KeCheng's APIs on import alert after it ignored FDA records requests.
High risk